<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007652</url>
  </required_header>
  <id_info>
    <org_study_id>125-102</org_study_id>
    <nct_id>NCT05007652</nct_id>
  </id_info>
  <brief_title>A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma</brief_title>
  <official_title>A Clinical Trial of KRN125 to Mobilize Hematopoietic Stem Cells Into Peripheral Blood in Patients With Multiple Myeloma and Malignant Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic&#xD;
      stem cells into the peripheral blood in patients with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with multiple myeloma.</measure>
    <time_frame>Day 5, 6, 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with malignant lymphoma.</measure>
    <time_frame>Day 1, 4, 5, 6, 7</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day 30 or initiation of radiotherapy or chemotherapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum KRN125 concentrations</measure>
    <time_frame>Day 30 or initiation of radiotherapy or chemotherapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Anti-KRN125 antibody</measure>
    <time_frame>Day 30 or initiation of radiotherapy or chemotherapy</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Multiple Myeloma and Malignant Lymphoma</condition>
  <arm_group>
    <arm_group_label>multiple myeloma cohort (KRN125)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple myeloma cohort (KRN8601)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>malignant lymphoma cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRN125(pegfilgrastim), PLR001(plerixafor)</intervention_name>
    <description>7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.</description>
    <arm_group_label>malignant lymphoma cohort</arm_group_label>
    <arm_group_label>multiple myeloma cohort (KRN125)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRN8601(filgrastim), PLR001(plerixafor)</intervention_name>
    <description>400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.</description>
    <arm_group_label>multiple myeloma cohort (KRN8601)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria for the multiple myeloma cohort&#xD;
&#xD;
          -  Patients with histologically or pathologically diagnosed multiple myeloma&#xD;
&#xD;
          -  Patients who achieved CR, sCR, VGPR, and PR with induction therapy Criteria for the&#xD;
             malignant lymphoma cohort&#xD;
&#xD;
          -  Patients with histologically or pathologically diagnosed malignant lymphoma&#xD;
&#xD;
          -  First or second CR or PR Multiple myeloma cohort, malignant lymphoma cohort common&#xD;
             criteria&#xD;
&#xD;
          -  Patients aged 20 to 75 years or younger at the time of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who received allogeneic hematopoietic stem cell transplantation (Allo-SCT),&#xD;
             autologous hematopoietic stem cell transplantation (ASCT), or CAR-T therapy&#xD;
&#xD;
          -  Patients who have developed adverse events leading to discontinuation of hematopoietic&#xD;
             stem-cell collection due to administration of granulocyte colony-stimulating factor&#xD;
             (G-CSF) or apheresis&#xD;
&#xD;
          -  Patients who have not been able to collect adequate amounts of hematopoietic stem&#xD;
             cells with G-CSF or plerixafor administration&#xD;
&#xD;
          -  Patients with hypersensitivity to G-CSF or plerixafor&#xD;
&#xD;
          -  Patients with ECOG Performance status (PSs) of 2 or greater.&#xD;
&#xD;
          -  Patients whose cardiac or pulmonary conditions were judged to be inappropriate for&#xD;
             apheresis or ASCT.&#xD;
&#xD;
          -  Pregnant or breastfeeding female patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Kirin Co., Ltd.</last_name>
    <phone>+81-3-5205-7200</phone>
    <email>clinical.info.jp@kyowakirin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hokkaido University Hospital of the National University Corporation</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

